Data Sheet (Cat.No.T68102)

TargetMol

Mitoquidone

Chemical Properties



CAS No. : 91753-07-0

Formula: C20H13NO2

Molecular Weight: 299.32

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Mitoquidone, a novel pentacyclic pyrroloquinone, is a potential anticancer agent. Mitoquidone showed good activity in a range of experimental solid tumour models and did not exhibit significant cytotoxicity.
Targets(IC50)	Others
In vivo	Mitoquidone (MTQ) demonstrated good activity in a range of experimental solid tumour models, but was weakly active against standard prescreens such as the P388 murine leukaemia. Twenty-seven patients were treated with MTQ given as a 4-h infusion either once every 21 days (150-600 mg/m2), once a week (200 mg/m2 per week), or as 5 daily doses repeated every 28 days (60-180 mg/m2 per day). Temporary remission of B-symptoms occurred in two patients with lymphoma. Linear pharmacokinetics were observed with a terminal plasma half-life of 2.9 +/- 2.1 h (n = 18 doses). The volume of distribution was 3.4 +/- 2.6 l/kg and plasma clearance was 629 +/- 469 ml/min per m2. [1]

Solubility Information

Solubility	DMSO: < 1 mg/mL (insoluble or slightly soluble) H2O: < 1 mg/mL (insoluble or slightly soluble) (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.3409 mL	16.7045 mL	33.4091 mL
5 mM	0.6682 mL	3.3409 mL	6.6818 mL
10 mM	0.3341 mL	1.6705 mL	3.3409 mL
50 mM	0.0668 mL	0.3341 mL	0.6682 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Speth PA, et al. Phase I and pharmacokinetic studies with the pentacyclic pyrroloquinone mitoquidone. Cancer Chemother Pharmacol. 1988 ; 21(4):343-346.